Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceutical

Related Keywords

Jukka ,Lapland ,Finland ,Boston ,Massachusetts ,United States ,Helsinki ,Eteläuomen Läi ,Mary Jane Elliott ,Lindsey Neville ,Sandy Jamieson ,David Daley ,Mika Kontro ,Markku Jalkanen ,Jo Turner ,Juha Karttunen ,Christopher Golden ,Drug Administration ,Peel Hunt ,Cairn Financial Advisers ,Faron Pharmaceuticals Ltd ,Helsinki University Hospital Comprehensive Cancer Center ,First North ,Associate Professor ,Principal Investigator ,Chief Executive Officer ,Project Optimus ,Jane Elliott ,Certified Adviser ,Nasdaq First ,Us Food And Drug Administration ,Faron Pharmaceuticals ,Multicenter Study ,Dose Levels ,The Company ,Standard Of Care ,Company ,